97277 ⎘
Immunoglobulins specific features characterized by immunoglobulin fragments; Constant or Fc region; Isotype CH3 domain
FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USE
#2BCMA VH-ONLY CARS
#3MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES
#4PH-DEPENDENT ANTI-CD3 ANTIBODIES AND METHODS RELATING THERETO
#5IL-2 PROCYTOKINE ANTIBODY FUSION PROTEINS
#6MULTISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD22 AND 4-1BB AND METHODS OF USE THEREOF
#7ANTI-SLC3A2-APIS ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
#8METHODS OF PRODUCING HETERODIMERIC ANTIBODIES
#9CANINE ANTIBODY MUTANTS
#10PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF
#11ENGINEERED IMMUNOCYTOKINES, FUSION POLYPEPTIDES, AND IL10 POLYPEPTIDES
#12METHODS AND COMPOSITIONS FOR CANCER TREATMENT
#13BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#14BISPECIFIC ANTI-VEGF/ANG2 ANTIBODY FORMULATION
#15BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#16ANTI-HER2 ANTIBODIES AND METHODS OF USE THEREOF
#17MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS
#18FCeRI BINDING PROTEIN
#19ANTI-CCR8 ANTIBODIES
#20Cµ4 REGION FOR PAIRING HEAVY AND LIGHT CHAINS IN MULTI-SPECIFIC ANTIBODIES
#21FUSIONS WITH CD8 ANTIGEN BINDING MOLECULES FOR TREATING CHRONIC VIRAL INFECTION
#22MULTIVALENT FZD4, WNT CO-RECEPTOR, AND VEGF BINDING MOLECULES AND USES THEREOF
#23Heavy Chain Constant Regions with Reduced Binding to Fc Gamma Receptors
#24ANTI-GPRC5D ANTIBODY AND USE THEREOF
#25ORTHOGONAL MUTATIONS FOR HETERODIMERIZATION
#26EQUINE ANTIBODY MUTANTS
#27BISPECIFIC CD16A BINDERS
#28ANTIGEN BINDING MOLECULES TO CD3 AND CD19
#29MULTIVALENT FZD4, WNT CO-RECEPTOR, AND VEGF RECEPTOR MOLECULES AND USES THEREOF
#30CHIMERIC ANTIGEN RECEPTORS FOR REMOVAL OF AMYLOID
#31PROTEASE-ACTIVATED T CELL BISPECIFIC MOLECULES
#32BISPECIFIC ANTIBODY AND APPLICATION THEREOF
#33VEGF ANTAGONISTS AND METHODS OF USE THEREOF
#34TETRAVALENT MULTISPECIFIC ANTIBODIES
#35ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED ANTIBODY VARIABLE REGION
#36Modified IgG1 Fc Domains and Anti-CD40 Domain Antibody Fusions Therewith
#37CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE
#38COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS AND ANTI-PD-1 ANTIBODIES
#39HETERODIMERIC FC-CLEC-1 FUSION MOLECULE AND USES THEREOF
#40ANTIBODIES BINDING TO FIBROBLAST ACTIVATION PROTEIN ALPHA AND DEATH RECEPTOR 4
#41METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#42Compositions and Methods for Inhibiting T Cell Exhaustion
#43BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#44MODIFIED ANTIBODIES AND USES THEREOF
#45Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof
#46RNA COMPOSITIONS TARGETING HIV
#47ANTIBODIES THAT BIND TO NATIVELY FOLDED MYOCILIN
#48RECOMBINANT BINDING PROTEINS WITH ACTIVATABLE EFFECTOR DOMAIN
#49COMBINATION THERAPY METHODS WITH T-CELL ENGAGING MOLECULES FOR TREATMENT OF PROSTATE CANCER
#50Fc VARIANTS WITH ALTERED BINDING TO FcRn
#51ANTI-CHIKV ANTIBODIES AND USES THEREOF
#52NOVEL METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX
#53EPCAM-CD3 EPSILON BISPECIFIC ANTIBODIES
#54ANTI-TNF-ALPHA ANTIBODIES AND COMPOSITIONS
#55FCRN/HSA BINDING MOLECULES AND METHODS OF USE
#56CD38 ANTIBODIES AND USES THEREOF
#57MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#58ANTI-TIGIT AND ANTI-PVRIG IN MONOTHERAPY AND COMBINATION TREATMENTS
#59TARGETING GDF15-GFRAL PATHWAY
#60ANTI-PCRV AND PSL BISPECIFIC ANTIBODIES FOR TREATMENT OF BRONCHIECTASIS
#61POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#62METHODS OF TREATING CANCER USING TRISPECIFIC BINDING PROTEINS TARGETING HER2-EXPRESSING TUMORS
#63COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS
#64FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME
#65ANTI-MESOTHELIN ANTIBODIES
#66METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX
#67METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
#68METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
#69FC BINDING FRAGMENTS COMPRISING AN OX40 ANTIGEN-BINDING SITE
#70ANTIGEN-BINDING PROTEINS AND RELATED METHODS OF USE
#71ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137
#72PAYLOAD-BEARING MULTISPECIFIC ANTIBODIES
#73Cancer Treatment comprising an anti-MSLN/CD137 antibody and a chemotherapeutic
#74COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS
#75METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES
#76CLDN18.2-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND USE THEREOF
#77FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USE
#78PSMA AND CD3 BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS
#79IL10RB BINDING MOLECULES AND ENCODING NUCLEIC ACIDS
#80BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES
#81BINDING AGENTS AND METHODS OF USE THEREOF
#82IL10 AGONISTS AND METHODS OF USE THEREOF
#83POLYPEPTIDE VARIANTS AND USES THEREOF
#84STABILIZATION OF FC-CONTAINING POLYPEPTIDES
#85RECOMBINANT RECEPTORS BINDING B CELL ACTIVATION FACTOR RECEPTOR AND USES THEREOF
#86MULTISPECIFIC BINDING AGENTS TARGETING DOPAMINE RECEPTOR D2 AND METHODS OF USE THEREOF
#87BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING CD19 AND CD3, AND USES THEREOF
#88HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
#89MULTISPECIFIC ANTIBODIES TARGETING CD79B/CD3 AND THE USES THEREOF
#90RECOMBINANT T CELL RECEPTORS
#91ANTI-MUC17 NANOBODY AND USE THEREOF
#92METHODS OF ENGINEERING TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
#93IL-18BP ANTAGONIST ANTIBODIES AND THEIR USE IN MONOTHERAPY AND COMBINATION THERAPY IN THE TREATMENT OF CANCER
#94Masked Multispecific Antigen-Binding Molecules with Cleavable Linkers
#95Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties for Use in Treating Cancer, Immunological Disorders, and Methods Thereof
#96ENGINEERED POLYPEPTIDES AND USES THEREOF
#97EXPRESSION TECHNOLOGY FOR ANTIBODY CONSTRUCTS
#98BISPECIFIC ANTIBODY
#99STABLE Fc FRAGMENTS, CONJUGATES, COMPOSITIONS, AND METHODS OF USE
#100BI- OR MULTI-SPECIFIC ANTIBODY
#101PSMA ANTIBODIES AND USES THEREOF
#102MULTIFUNCTIONAL BISPECIFIC FUSION POLYPEPTIDE
#103MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#104ANTIBODY MOLECULES
#105ROR1-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES
#106Anti-CD98hc VNARs for Crossing the Blood Brain Barrier and Type IV VNAR Libraries
#107HETERODIMER MOLECULE BASED ON CH3 DOMAIN, AND PREPARATION METHOD AND USE THEREOF
#108Anti-CD28 Antibodies and Methods of Use Thereof
#109CYTOTOXICITY-INDUCING THERAPEUTIC AGENT
#110TRISPECIFIC BINDING PROTEINS, METHODS, AND USES THEREOF
#111TRISPECIFIC BINDING PROTEINS, METHODS, AND USES THEREOF
#112BISPECIFIC ANTIBODIES THAT BIND TO NKP46 AND MICA/B
#113DNA THERAPEUTIC ENCODING AN ANTIBODY OR ANTIGEN BINDING FRAGMENT
#114ANTIGEN-BINDING PROTEIN COMPRISING TWO FC DOMAINS AND USE THEREOF
#115TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODY
#116Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
#117SEPARATION OF TRIPLE-LIGHT CHAIN ANTIBODIES USING CATION EXCHANGE CHROMATOGRAPHY
#118ANTI-CD39 NANOBODY AND USES THEREOF
#119VARIANT ANTIBODIES THAT BIND GAMMA-DELTA T CELL RECEPTORS
#120Fc VARIANTS WITH ALTERED BINDING TO FcRn
#121VARIANT CH3 DOMAINS ENGINEERED FOR PREFERENTIAL CH3 HETERODIMERIZATION, MULTI-SPECIFIC ANTIBODIES COMPRISING THE SAME, AND METHODS OF MAKING THEREOF
#122ANTIBODY VARIANTS AND USES THEREOF
#123CD19 BINDING MOLECULES AND USES THEREOF
#124ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF
#125FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USE
#126PH-DEPENDENT HSA-BINDING MOLECULES AND METHODS OF USE
#127ANTIBODY DRUG-CONJUGATES TARGETING C-MET AND METHODS OF USE THEREOF
#128MULTISPECIFIC NK ENGAGER PROTEIN
#129COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#130VARIANT CH3 DOMAINS ENGINEERED FOR PREFERENTIAL CH3 HETERODIMERIZATION, MULTI-SPECIFIC ANTIBODIES COMPRISING THE SAME, AND METHODS OF MAKING THEREOF
#131CANINIZED HUMAN ANTIBODIES TO HUMAN IL-4R ALPHA
#132METHOD FOR IN VIVO GENERATION OF MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
#133ILT3 AND CD3 BINDING AGENTS AND METHODS OF USE THEREOF
#134NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERING
#135STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAIN
#136BISPECIFIC ANTIBODIES WITH CLEAVABLE C-TERMINAL CHARGE-PAIRED TAGS
#137Novel formats of anti-CD28/sPD-1 fusion constructs
#138IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS
#139Anti-ED-A Antibodies for the Treatment of Pulmonary Hypertension
#140Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV
#141PH-SELECTIVE ANTIBODY FC DOMAINS
#142GLYCOSYLATED FC VARIANTS WITH IMPROVED SELECTIVE BINDING AFFINITY TO FCyRIIIA
#143MULTISPECIFIC ANTIBODIES AND USES THEREOF
#144Method of Treating an Eosinophil-Associated Disease
#145COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND CMET
#146COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDING
#147TREATMENT WITH AN ANTIBODY THAT BINDS EGFR AND CMET
#148USE OF FCRN ANTAGONISTS FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS
#149METHODS FOR THE TREATMENT OF MULTIPLE MYELOMA
#150IL27RAlpha BINDING MOLECULES AND METHODS OF USE
#151ENPP3 AND CD3 BINDING AGENTS AND METHODS OF USE THEREOF
#152BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS
#153COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRING
#154PROTEINASE 3 (PR3) CHIMERIC AUTOANTIBODY RECEPTOR T CELLS AND RELATED METHODS AND USES
#155MULTIVALENT LINKERS USED FOR ANTIBODY LABELING
#156ENGINEERED ALPHA KLOTHO POLYPEPTIDES AND USES THEREOF
#157METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#158HIGH CONCENTRATION ANTI-C5 ANTIBODY FORMULATIONS
#159HUMAN IGG1 FC REGION VARIANTS AND USES THEREOF
#160BISPECIFIC ANTIBODY AND APPLICATION THEREOF
#161ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
#162DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AND ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
#163CHIMERIC ANTIGEN RECEPTORS BINDING STEAP1
#164ANTI-HER2 ANTIBODIES AND METHODS OF USE THEREOF
#165METHODS FOR ADMINISTERING A BCMAXCD3 BINDING MOLECULE
#166ANTI-B7-H4 ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#167Anti-PD-1 Antibodies and Fusion Proteins
#168STABILIZED CD3 ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF
#169DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
#170COMPOSITIONS AND METHODS FOR TREATING DISEASE
#171DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AND ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
#172BISPECIFIC ANTIGEN BINDING CONSTRUCTS TARGETING HER2
#173IGG1 FC MONOMER AND APPLICATION THEREOF
#174ANTIBODY OPTIMIZATION
#175ANTIBODY VARIANTS
#176Anti-Polyubiquitin Multispecific Antibodies
#177HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
#178HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38
#179CHIMERIC HEAVY CHAIN CONSTANT DOMAINS WITH REDUCED BINDING TO FC GAMMA RECEPTORS AND USES THEREOF
#180ACTIVATABLE BISPECIFIC ANTI-CD3 AND ANTI-PD-L1 PROTEINS AND USES THEREOF
#181METHOD FOR PRODUCING AN ANTIBODY PEPTIDE CONJUGATE
#182ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
#183ANTI-MET FAB-FC FOR THE TREATMENT OF A TUMOR AND/OR METASTASIS
#184COMBINATIONS OF ANTIGEN BINDING MOLECULES
#185ANTIBODY/DRUG CONJUGATES AND METHODS OF USE
#186ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF
#187METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#188METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
#189FC BINDING FRAGMENTS COMPRISING A CD137 ANTIGEN-BINDING SITE
#190FC-GAMMA RECEPTOR II BINDING AND GLYCAN CONTENT
#191ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES
#192BISPECIFIC BINDING PROTEINS AND USES THEREOF
#193BISPECIFIC ANTIBODIES AGAINST HER2
#194MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
#195STEAP2 DIRECTED T-CELL ENGAGERS AND COMPOSITIONS THEREOF
#196ANTIBODY VARIANTS AND USES THEREOF
#197IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS
#198TRIVALENT TRISPECIFIC ANTIBODY CONSTRUCTS
#199FELINE ANTIBODY VARIANTS
#200BISPECIFIC IGG ANTIBODIES AS T CELL ENGAGERS
#201PRODUCTION OF HETEROMULTIMERIC PROTEINS USING MAMMALIAN CELLS
#202HER3 ANTIGEN-BINDING MOLECULES
#203PROTEINS COMPRISING CD20 BINDING DOMAINS, AND USES THEREOF
#204IMMUNOMODULATORY TRISPECIFIC T CELL ENGAGER FUSION PROTEINS
#205Optimized CD3 Antigen Binding Domains
#206MULTI-SPECIFIC LIGAND BINDERS
#207ANTIBODIES SPECIFIC FOR CD70 AND THEIR USES
#208Fc VARIANTS WITH ALTERED BINDING TO FcRn
#209FUSION PROTEINS OF HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH ENHANCED COMPLEMENT BINDING
#210COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
#211SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
#212BENZODIAZEPINE DERIVATIVES AND ANTIBODY CONJUGATES THEREOF
#213Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#214ANTIBODIES BINDING TO FIBROBLAST ACTIVATION PROTEIN ALPHA AND DEATH RECEPTOR 4
#215MULTISPECIFIC ANTIBODIES BINDING TO CD20, NKP46, CD16 AND CONJUGATED TO IL-2
#216MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY
#217METHOD OF MANUFACTURING BISPECIFIC ANTIBODIES, BISPECIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES
#218TRANSGENIC MICE WITH HUMANIZED MHC I AND IMMUNOGLOBLUIN HEAVY CHAIN GENES
#219TRANSGENIC MICE WITH HUMANIZED MHC I AND IMMUNOGLOBLUIN HEAVY CHAIN GENES
#220NOVEL PD-1 BINDING DOMAINS
#221NOVEL PD-1 BINDING DOMAINS
#222MULTISPECIFIC ANTIBODIES AND USES THEREOF
#223BCMA CHIMERIC ANTIGEN RECEPTORS
#224Trispecific Engineered Antibodies
#225COMPOSITIONS COMPRISING ANTIGEN-BINDING MOLECULES
#226Linker Polypeptides
#227MONOVALENT ASYMMETRIC TANDEM FAB BISPECIFIC ANTIBODIES
#228ANTIBODY MASKS AND USES THEREOF
#229MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION WITH ANTI PD-1 ANTIBODIES FOR TREATING CANCERS
#230MULTISPECIFIC ANTIBODIES AND USES THEREOF
#231CAIX TARGETING IL-12 FUSION PROTEINS AND METHODS OF USE THEREOF
#232MULTISPECIFIC PROTEINS BINDING TO NKP46, A CYTOKINE RECEPTOR, A TUMOUR ANTIGEN AND CD16A
#233POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#234CD20 AND CD22 TARGETING ANTIGEN-BINDING MOLECULES FOR USE IN PROLIFERATIVE DISEASES
#235IL23R BINDING MOLECULES AND METHODS OF USE
#236MULTISPECIFIC ANTIBODIES FOR USE IN TREATING DISEASES
#237Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors
#238BISPECIFIC ANTIGEN BINDING CONSTRUCT
#239HETERODIMERIC PROTEINS
#240ORTHOGONAL MULTIMERIC PROTEINS
#241CD47/PD-L1-TARGETING PROTEIN COMPLEX AND METHODS OF USE THEREOF
#242BISPECIFIC ANTI-CCL2 ANTIBODIES
#243MODIFIED IMMUNOGLOBULINS
#244DIMERIC PROTEIN COMPLEXES AND USES THEREOF
#245METHODS FOR PURIFYING HETEROMULTIMERIC ANTIBODIES
#246METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES
#247Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
#248CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS
#249CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF
#250COMPOSITIONS AND METHODS FOR AUGMENTING ANTIBODY MEDIATED RECEPTOR SIGNALING
#251MULTISPECIFIC ANTIGEN-BINDING PROTEIN AND USE THEREOF
#252BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS
#253Fc VARIANTS WITH ALTERED BINDING TO FcRn
#254COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE
#255VACCINE MOLECULES
#256ANTIBODIES THAT BIND PSMA AND GAMMA-DELTA T CELL RECEPTORS
#257Binding agents targeting TROP2-expressing tumor cells
#258BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS
#259ANTIBODIES AGAINST PD-L1
#260ANTI-CD3 ANTIBODIES
#261NOVEL MULTISPECIFIC ANTIBODIES
#262METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#263PD-1 ANTIBODIES, POLYPEPTIDES AND USES THEREOF
#264BISPECIFIC ANTIBODY AND USE THEREOF
#265OLIGONUCLEOTIDE CONJUGATES TARGETED TO THE TRANSFERRIN RECEPTOR
#266RECOMBINANT PROTEINACEOUS BINDING MOLECULES
#267HETERODIMERIC IGA FC CONSTRUCTS AND METHODS OF USE THEREOF
#268USES OF NK CELL ENGAGING ANTIBODY FUSION CONSTRUCTS FOR TREATMENTS
#269HIDE1 COMPOSITIONS AND METHODS
#270MULTIMERIC PROTEIN PURITY DETERMINATION
#271TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS
#272Methods of engineering transferrin receptor binding polypeptides
#273METHODS OF ENGINEERING TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
#274ENGINEERED ANTIBODY FC VARIANTS FOR ENHANCED SERUM HALF LIFE
#275ANTIGEN-BINDING MOLECULE COMPRISING ALTERED ANTIBODY VARIABLE REGION BINDING CD3 AND CD137
#276NOVEL ANTIBODY FORMAT
#277CHIMERIC IMMUNOGLOBULIN
#278PRECURSOR PROTEINS AND KIT FOR TARGETED THERAPY
#279TRISPECIFIC ANTIBODY AND PREPARATION METHOD THEREFOR AND USE THEREOF
#280MODIFIED FCRN BINDING FRAGMENTS WITH IMPROVED HALF-LIFE
#281COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE
#282COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE
#283Fc VARIANTS WITH ALTERED BINDING TO FcRn
#284ANTIBODIES BINDING TO CD30 AND CD3
#285VECTORED PROPHYLAXIS OF SARS-COV-2
#286MULTISPECIFIC ANTIGEN-BINDING PROTEIN AND USE THEREOF
#287FC-REGION VARIANTS WITH MODIFIED FCRN-BINDING PROPERTIES
#288FC-DERIVED POLYPEPTIDES
#289IL-2 PROCYTOKINE ANTIBODY FUSION PROTEINS
#290POLYPEPTIDE LINKER FOR PREPARING MULTISPECIFIC ANTIBODIES
#291HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF
#292BINDING MOLECULES THAT BIND CD137 AND PD-L1
#293Compositions and methods related to IL27 receptor binding
#294MULTITARGETING BISPECIFIC ANTIGEN-BINDING MOLECULES OF INCREASED SELECTIVITY
#295USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
#296GP130 Binding Molecules and Methods of Use
#297MESOTHELIN BINDING MOLECULE AND APPLICATION THEREOF
#298Balanced Charge Distribution in Electrostatic Steering of Chain Pairing in Multi-specific and Monovalent IgG Molecule Assembly
#299MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS
#300Multi-Specific Molecules